ABSTRACT

Background: Pseudo-allergic reactions against aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) are quite frequent.

Objective: Our aim was to determine tolerance of Celecoxib, a selective inhibitor of cyclooxygenase-2 (Cox-2,) by oral challenge test in patients who showed skin reactions (diffuse erythema or urticaria/angioedema) after taking ASA and/or NSAIDs.

Methods: The oral challenge test was carried out in single-blind on 86 patients treated with a 200 mg cumulative dose of Celebrex, administered in 3 or 4 visits at 48-72 hours interval.

Results: Only 4 patients showed mild skin reactions. In addition, we observed 37 patients with osteoarthrosis taking a 200-400 mg/day dose of Celebrex 5-6 times a week, over a period of 75 days. At day 36, we observed in a single patient urticarial phenomena appeared on the chest and the back.

Conclusions: Our study proves therefore Celecoxib safety on a 72-hour observation period.

Key words: ASA-NSAIDs. Celecoxib. Cutaneous reactions. Intolerance. Safety.

INTRODUCTION

Acetylsalicylic acid (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) represent one of the pharmacotherapeutic groups mainly used as analgesic and anti-inflammatory drugs not only in orthopaedic-rheumatologic, but also in otological, odontological and gynaecological pathologies. However ASA and NSAIDs may cause side effects involving kidneys, liver and in particular the gastrointestinal tract. Pseudo-allergic reactions (asthma, urticaria) against ASA and NSAIDs involve 0.3 to 0.5 % of the overall population. This kind of reactions considerably increases in patients with bronchial asthma and in particular in those with concomitant nasal polyposis, thus reaching a rate of 20 to 30 %. Twenty-one to 30 % of patients with chronic urticaria also show pseudo-allergic phenomena against such group of drugs. Even subjects who do not suffer from asthma or urticaria may however develop urticarial and/or angioedematous eruptions after taking ASA or NSAIDs.

There is a high uniformity of opinions towards the concept that the anti-inflammatory activity of ASA and NSAIDs rises from the inhibition of COX-2, while undesirable side effects are the result of the COX1’s block.

The purpose of the present study is to determine the clinical tolerance of Celecoxib (a 1.5 diaryl-pyrazole-base compound), a specific COX-2 inhibitor, in patients with a clinical history of pseudo-allergic skin reactions (diffuse erythema or urticaria/angioedema) due to ASA and NSAIDs in patients with multiple drug-induced urticaria-angioedema according to the classification of Stevenson et al.
PATIENTS AND METHODS

Ninety-eight patients (63 women and 35 men) aging from 46 to 69 years (mean age 55.2) were enrolled in the study, all suffering from osteoarthrosis. Patient enrolment was carried out with the following criteria (table I):

1. Proven intolerance against oral administration of ASA/NSAIDs with phenomena of diffuse erythema or urticaria/angioedema, as resulting from anamnestic data and admission visit at the allergy outpatient’s service;
2. Appearance of the above-mentioned skin eruptions during at least the 4-5 months before the beginning of the study, but not during the latest 3 weeks;
3. No administration of antihistaminic drugs over the 8 to 10 days before the oral challenge test.

Subjects suffering from asthma and/or ASA-induced asthma have not been included in the study. In agreement with the SIAIC (Italian Society of Allergy and Clinical Immunology) Memorandum 11, we did not carry out any oral challenge test with ASA/NSAIDs, due to ethical reasons, in order to avoid possible severe adverse reactions 12, and because the clinical history was sufficient to reach a diagnosis. Patients taking beta-blockers or ACE-inhibitors or with contraindications for epinephrine administration were not enrolled in the study. In order to exclude any adverse reaction due to the prolonged administration of the drug, we observed 44 patients with osteoarthrosis, who were treated with a 200-400 mg/day dose of the drug 5-6 times a week, over a period of 75 days. Each patient signed an informed consent. A single-blind oral challenge test was carried out (table II), and the patients were observed 6, 24, 48, 72 hours after the last drug intake to verify the eventual onset of late responses.

RESULTS

Due to the fact that 3 out of 32 patients showed urticarial eruptions on the chest and the back 2-3 hours after the first administration of the 100 mg dose, we decided to continue with a more progressive schedule in the remaining 54 patients (table III).

By adopting the second schedule, only one patient showed mild erythema 3 hours after the cumulative administration of 200 mg dose of Celecoxib.

Just in one patient urticarial pomeii on the back and the chest were reported on the day 36. No patient complained mild or severe gastroenteric disorders, but just mild pyrosis that was well-controlled with the administration of drugs containing magnesium and aluminium hydroxide, while osteoarthritic signs and symptoms have showed good improvement.

DISCUSSION

An allergic mechanism of such affections was never established because the skin-tests carried out with ASA-lysine always reported negative results, the same as the several investigations performed to try to detect specific antibodies 13.

The cyclooxygenase theory that Szczeklik proposed in 1990 13 was confirmed by the subsequent studies 14-17. ASA and NSAID intolerance would be caused by the inhibition of cyclooxygenase with the block of the prostaglandin formation and deviation towards the pathway of the 5-lipooxygenase, with the production of cysteinil-leucotrienes LTC 4, LTD 4 and LTE 4 13,16,18.
NSAIDs and ASA inhibit both cyclooxygenase isoforms (COX-1 and COX-2), but with different intensities. At low doses, acetaminophen weakly inhibits both COX-1 and COX-2, and nimesulide induces a relative inhibition of COX-1 and a lower inhibition of COX-2. COX-1 is a constitutive enzyme existing in mast cells and tissues where it produces prostaglandins that are important for preserving homeostatic functions, e.g., the maintenance of renal and gastrointestinal function's integrity. COX-2 is instead an inducible enzyme whose synthesis is rapidly and temporarily induced as a result of tissue damages, inflammatory, allergic and immune stimuli.

Various authors reported a good Celecoxib tolerance in patients complaining bronchial asthma attacks (not object of present study) due to the administration of ASA/NSAIDs or, showing skin reactions. However, there are reports about Celecoxib-induced anaphylactoid reactions or severe toxicodermia. It is important to notice that in the study made by Marques et al., Celecoxib was administered to the patient in association with aceterminophene and codeine. A maculopapular reaction and a Sweet's syndrome, or acute febrile neutrophilic dermatosis were also observed after the administration of Celecoxib.

The Australian Adverse Drug Reactions Bulletin reported also urticarial reactions. Mommens et al. and Sanchez-Borges reported a glottis oedema in a publication that however ended with the following conclusion: “In general, most NSAID-sensitive patients tolerate COX-2 inhibitors without any reaction. If challenge tests are positive, strict avoidance of all NSAIDs is mandatory.”

A cross reaction was observed between Celecoxib and sulphotiamoxazole. The subsequent publications do not confirm this cross-reaction because antimicrobial sulphonamides contain an aromatic aminogroup, and, in particular, in sulphamethoxazole the sulphonamide is bound to a methylated heterocyclic ring or aminogroup, and, in particular, in sulphamethoxazole, or showing skin reactions. According to Knowles et al., the adverse side-effects are attributed to the heterocyclic ring or to the aromatic aminogroup that are not present in Celecoxib, as previously reported.

The oral challenge test, one of us successfully employed nimesulide, imidazole salicylate as an alternative to ASA and NSAIDs. Despite the publication of Fradet et al. that described a hypersensitivity syndrome against Celecoxib characterized by toxic skin reactions, fever and liver involvement (increased serum transaminase, CK, and γGT), we can agree with the studies carried out by Deeks et al. and by Moskowitz et al., which state the efficacy and the safety of Celecoxib in the treatment of osteoarthritis. An original aspect of recent studies in respect to literature is the length of the observation period after the challenge tests (24, 48 and 72 hours), and during the Celecoxib treatment to verify its tolerability (75 days, in 37 out of 86 patients in study).

REFERENCES

10. Ispano M, Fontana A, Sobilla J, Otoneri C. Oral challenge with alternative non steroidal antiinflammatory drugs (NSAIDs) and paracetamol in patients intolerant to these agents. Drugs 1993;46(suppl 1):253-6.
19. Wallace JL. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the cateto-
20. Souss A, Pistor R, Christe PE, Lane SJ, Nasser SM, Schmitz-
Schumann M, et al. Enhanced expression of cyclo-oxygenase isoenzyme-2 (COX-2) in asthmatic airways and its cellular dis-
Dahlen B, Szeczulita A, Murray JJ. Celecoxib in patients with
asthma and aspirin intolerance. The Celecoxib in Aspirin-Intol-
22. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F,
Perez CR. Tolerability to new COX-2 inhibitors in NSAID-sen-
sitive patients with cutaneous reactions. Ann Allergy Asthma
Immunol 2001;87:201-4.
23. Woessner KM, Simon RA, Stevenson DD. The safety of Cele-
coxib in patients with aspirin-sensitive asthma. Arthritis Rheum
24. Martin-Garcia C, Hinjojoa M, Barajas P, Camacho E, Garcia-
Rodriguez R, Alfaya T. Celecoxib, a highly selective COX-2 in-
hibitor, is safe in aspirin-induced asthma patients. J Invest All-
25. Garcia-Rodriguez RM, Hinjojoa M, Camacho-Garrido E,
Borges-Gimeno P, Martin-Garcia C. Celecoxib, safe in NSAID
26. Senna GE, Bilo MB, Antonacci L. Tolerability of three selective
cyclo-oxygenase-2 inhibitors, meloxicam, Celecoxib and rofe-
coxib in NSAID-sensitive patients. Eur Ann Allergy Clin Im-
27. Liccior G, Sambito A, Piccolo A, Sanna GE, Piscitelli D, D'Ama-
to M. Safety of Celecoxib in patients with adverse skin reac-
tions to acetaminophen (paracetamol) and nimesulide associ-
ated or not with common non-steroidal anti-inflammatory
29. Viola M, Quarantino D, Garcia F, Caringh M, Valuzzi R, Caruso
C, Volpato S, Romano A. Celecoxib tolerability in patients with
hyperactivity (mainly cutaneous reactions) to nonsteroidal
anti-inflammatory drugs. Int Arch Allergy Immunol 2006;137:
145-50.
30. Stevenson DD, Sanchez-Borges M, Szeczulita A. Classification of
allergic and pseudallergic reactions to drugs that inhibit cy-
clooxygenase enzymes. Ann Allergy Asthma Immunol 2001;
87:177-80.
Anaphylactic shock induced by Celecoxib. Ann Int Med 2001;
135:395.
32. Levy MB, Fink JH. Anaphylaxis to Celecoxib. Ann Allergy
Immunol 2001;87:72-3.
33. Grob M, Pichler WJ, Wüthrich B. Anaphylaxis to Celecoxib. Al-
lergy 2002;57:284-5.
34. Gagnon R, Julien M, Gold P. Selective Celecoxib-associated
anaphylactic reaction. J Allergy Clin Immunol 2003;111:
1484-5.
35. Marques S, Milipied B, Fouil B, Barbarot S. Toxicodermies
graves aux Celecoxib (Celebrex). Ann Dermatol Venereol
2003;130:1051-5.
36. Grob M, Scheidegger P, Wüthrich B. Allergic skin reaction to
37. Fye KH, Crowley E, Berger TD, Le Bot P, Conolly MK. Cale-
45:302-2.
38. Adverse Drug Reactions Advisory Committee (ADRAC).
AustralIan adverse drug reactions bulletin. Celecoxib: early Aus-
Intolérance aux anti-inflammatoires non stéroïdiens inhibi-
teurs spécifiques de la cyclo-oxygénase 2. Rev Fr Allergol
2003;43:393-6.
40. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F.
Cutaneous reactions to aspirin and nonsteroidal antiinflamma-
41. Mc Morran M, Moein-Weikac C. Celecoxib (Celebrex): 1 year
42. Knowles S, Shapiro L, Shear NH. Should Celecoxib be con-
traindicated in patients who are allergic to sulfa remedies?
Revisiting the meaning of ‘sulfa’ allergy. Drug Saf 2001;24:
239-47.
43. Schuster C, Wüthrich B. Anaphylactic drug reaction to Cele-
coxib and sulphasalazine: cross reactivity or coincidence? Allergy
2003;58:1072.
44. Andri L, Senna GE, Bertelli C, Givanni S, Scarabazzari I,
Mezzalani F, et al. Tolerability of nimesulide in aspirin-sensitive
45. Senna GE, Andri L, Danna AR, Mezzalani F, Andri L. Tolerability
of imidazole salicylate in aspirin-sensitive patients. Allergy
46. Fradet G, Robin-Le Nahért A, Huguenn A, Chiffolaou A. Sin-
drome d’hypersensibilité au Celecoxib. Ann Med Intern
47. Deeks JJ, Smith LA, Global P, Bradley MD. Efficacy, tolerabili-
ty and upper gastrointestinal safety of Celecoxib for treatment
of osteoarthritis and rheumatoid arthritis: systematic review of
WW, Geis GS. American society pain questionnaire and
other pain measures in the assessment of osteoarthritis pain:
a pooled analysis of three celecoxib pivotal studies. Am J Ther